12 Health Care Stocks Moving In Thursday's After-Market Session
Portfolio Pulse from Benzinga Insights
In Thursday's after-market session, several healthcare stocks experienced significant movements. Atreca (BCEL) saw a substantial rise of 45.6%, while Evoke Pharma (EVOK) and INVO Bioscience (INVO) also posted gains. Conversely, HeartBeam (BEAT) and Alaunos Therapeutics (TCRT) were among the stocks that declined. These movements reflect changes in investor sentiment and could be indicative of company-specific news or broader market trends within the healthcare sector.
January 11, 2024 | 9:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Atreca's shares surged 45.6% to $0.34, significantly increasing the company's market value.
The substantial rise in Atreca's stock price could attract more investor attention in the short term, potentially leading to increased trading volume and continued upward price momentum.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Evoke Pharma's shares increased by 16.45% to $0.99, reflecting a positive market reaction.
Evoke Pharma's notable after-market gain suggests investor confidence, which may lead to further short-term price appreciation.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 90
POSITIVE IMPACT
INVO Bioscience's stock rose by 10.57% to $1.15, indicating positive investor sentiment.
The increase in INVO Bioscience's stock price may continue in the short term if the positive sentiment persists among investors.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 90
NEGATIVE IMPACT
HeartBeam's shares fell by 6.9% to $1.63, possibly due to negative market news or sentiment.
The decline in HeartBeam's stock price could indicate a bearish outlook from investors, which might lead to further short-term depreciation.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 90
NEGATIVE IMPACT
Alaunos Therapeutics' shares decreased by 6.74% to $0.13, suggesting a negative investor response.
The drop in Alaunos Therapeutics' shares could reflect investor concerns, potentially leading to further short-term price declines.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 90